<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5146">
  <stage>Registered</stage>
  <submitdate>20/09/2014</submitdate>
  <approvaldate>20/09/2014</approvaldate>
  <nctid>NCT02250495</nctid>
  <trial_identification>
    <studytitle>The Sympara VIBE Study for Hypertension</studytitle>
    <scientifictitle>VIBE: A Clinical Study to Evaluate the Sympara Therapeutic System for the Treatment of Hypertension</scientifictitle>
    <utrn />
    <trialacronym>VIBE</trialacronym>
    <secondaryid>STS1402</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Sympara Therapeutic System

Experimental: Sympara Therapeutic System - All subjects will wear for the Sympara device for 30 days


Treatment: devices: Sympara Therapeutic System
Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of subjects with serious, device-related adverse events as a measure of safety and tolerability</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects with a reduction in baseline blood pressure following 30 days of Sympara device use as a measure of efficacy - Evaluating change in office, home and ambulatory blood pressure measurements at 30 days compared to baseline</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Office systolic blood pressure of =150mmHg based on an average of three (3) blood
             pressure reading measured at both the initial screening visit and a confirmatory
             screening visit OR a mean daytime systolic blood pressure =135mm Hg on 24-hour
             Ambulatory Blood Pressure Measurement

          -  Receiving and adhering to an appropriate anti-hypertensive treatment regimen, as
             prescribed by physician

          -  Minimum six- (6) month history of diagnosis and treatment of hypertension</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous renal denervation or carotid barostimulation implant

          -  Secondary causes of hypertension or primary pulmonary hypertension

          -  Prior surgery or radiation to the area of the carotid sinus, or presence of a stent or
             other implant in the carotid artery

          -  Known or suspected baroreflex failure or significant orthostatic hypotension

          -  One or more hospital admissions for a hypertensive crisis within the past year

          -  History of myocardial infarction, fibrillation event, unstable angina pectoris,
             syncope, transient ischemic attach (TIA) or a cerebrovascular accident within six (6)
             months of the screening period, or has widespread atherosclerosis with documented
             intrasvascular thrombosis or unstable plaques

          -  Diabetes mellitus (Type 1)

          -  Chronic renal disease requiring dialysis

          -  Kidney or liver transplant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>8</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Monash Health - Clayton</hospital>
    <hospital>Barwon Health - Geelong</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3220 - Geelong</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sympara Medical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the VIBE study is to evaluate the efficacy and safety of the Sympara
      Therapeutic System in the treatment of hypertension</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02250495</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ian Meredith, AM, PhD</name>
      <address>Monash Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>